NeuroDerm Parkinson’s Drug Inches Closer To Market With Phase III Win

Mitsubishi Tanabe Pharma paid $1.1bn to acquire the Israeli biotech in 2017 for a drug that analysts forecast to represent a market opportunity worth up to $1.7bn in peak sales.

Mitsubishi Tanabe Pharma subsidiary NeuroDerm announced positive Phase III results from its Parkinson's drug trial • Source: Shutterstock

Mitsubishi Tanabe Pharma Corporation’s billion-dollar bid nearly six years ago for NeuroDerm Ltd. and its drug for Parkinson’s disease looks likely to pay off as the Israeli drug developer announced positive Phase III results from the drug, in a field that has seen considerable development and multiple billion-dollar collaboration deals in recent years.

NeuroDerm said 9 January that the Phase III BouNDless trial of ND0162 met its primary endpoint of “on” time without troublesome dyskinesia – also known as “good on” time – along with positive and clinically meaningful results for the key secondary endpoint of “off” time

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D